Galle P et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology front wo randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). (Abstract GS-09)
Bijwerkingen geen reden om te stoppen met vaccinatie, stellen hoogleraren
mei 2021 | Vaccinatie, Virale infecties